ChinaBio(R) LLC Release: Week in Review: China's JOINN Labs Buys Major Biopharma Campus in San Francisco

Published: Jan 14, 2013

by Richard Daverman, PhD

January 12, 2013 -- Joinn Laboratories, a China pre-clinical CRO, is the mystery buyer of the ex-Bayer biopharma campus in the San Francisco Bay area; Fosun Pharma, executing its growth-by-acquisition strategy, paid $93 million for a 78% stake in CNS drugmaker Hunan Dongting Pharma; Dahuanong Animal Health paid $25.4 million to purchase 60% of Foshan Standard Bio-tech; GrandPharma of China licensed China rights to Acetium capsules from Biohit Oyj, a Finish drugmaker; China was on the minds of JP Morgan Healthcare Conference attendees, with most companies including a China Strategy in their presentations; China’s government ordered price cuts that averaged 15% on 20 major groups of drugs, affecting many products from international big pharma; Zhifei’s vaccine for TB won SFDA approval to begin a Phase III trial; and EntreMed, a Washington DC-area biotech, filed an application with the SFDA to begin clinical trials of its triple-negative breast cancer treatment. More details…

Stock Symbols: (Xetra: BAY) (SHA: 600196; HK: 2196) (SHE: 300186) (SHE: 300122) (NSDQ: ENMD)

Back to news